Skechers USA Inc. (SKX)
Shares of SKX soared more than 10% to touch an all-time high during the extended session Wednesday after the company delivered record quarterly financial results, driven by continued strong demand for its product worldwide
For the second quarter 2015, SKX posted net sales of $800.5 million, a 36.35% increase year over year, and net earnings of $79.8 million, or $1.55 per diluted share, compared to net earnings of $34.8 million, or $0.68 per diluted share in the same quarter the prior year, surpassing the Capital IQ Consensus Estimate of $1.01 earnings per share on revenues of $739.8 million for the period
SKX said that it remains comfortable with the analysts’ current consensus estimates for the back half of 2015 and believes that its accelerated growth trend will remain through 2015 and into 2016.
SKX designs, develops and markets a diverse range of lifestyle footwear for men, women and children, as well as performance footwear for men and women.
More about Skechers USA Inc. (SKX) at www.skechers.com
Open Text Corp. (OTEX)
The price of OTEX stock surged over 9% in after-hours trading Wednesday as the company reported in its financial results quarterly revenue and profit numbers above Wall Street analysts’ expectations
For its fourth quarter fiscal 2015, OTEX posted revenues of $482.7 million and non-GAAP diluted earnings per share of $0.87, topping the Capital IQ Consensus Estimate of $0.68 earnings per share on revenues of $448.03 million.
On an adjusted basis, OTEX has delivered 7 year cumulative growth rates of 19% for non-GAAP EPS, 18% for operating cash flow and 22% for non-GAAP net income.
OTEX‘s Board of Directors has declared a cash dividend of $0.20 per common share, payable September 18, 2015 to shareholders of record as of August 28, 2015.
OTEX is the largest independent software provider of Enterprise Information Management
More about Open Text Corp. (OTEX) at www.opentext.com
DepoMed Inc. (DEPO)
After the closing bell on Wednesday, DEPO delivered record quarterly net product sales of $94.3 million for the second quarter 2015 in its financial results, up 234% versus the same period the prior year. The company has raised its 2015 product sales guidance to a range of $320 million to $340 million, which is essentially triple its 2014 sales.
Separately, DEPO said that its Board of Directors has unanimously rejected the purported revised, highly conditional, unsolicited and non-binding proposal from Horizon Pharma plc (HZNP).
On July 21, 2015, Horizon offered to acquire all outstanding common shares of DEPO in an all-stock transaction then valued at $33.00 per share. DEPO‘s Board concluded that the Proposal is inadequate and believes that Horizon’s offer substantially undervalues the company’s business and does not reflect the inherent value of DEPO in light of its standalone prospects.
DEPO is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders.
More about DepoMed Inc. (DEPO) at www.depomed.com.
Crown Equity Holdings Inc. (CRWE)
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
The company is currently developing its CRWE WORLD platform ( www.crweworld.com ), a network of community targeted sites which goal is to be a one-stop shop for the various needs of online consumers in a range of marketing specialties like Real Estate, Coupons & Deals, Business Directory and more
CRWE WORLD Network’s business model is based on selling advertising to businesses targeting their marketing message locally, nationally, internationally and also to target potential clients for an specific location as a zip code.
The company’s CRWE Real Estate ( www.CRWERealEstate.com ) is expected to be integrated in all the CRWE WORLD Network. It will allow people to submit their listings for exposure to visitors searching for homes.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE PR Finance www.finance.crwe-pr.com/disclaimer